Cardiac myosin inhibition in heart failure with normal and supranormal ejection fraction

JAMA Cardiology

2024-09-30

(Press-News.org) About The Study: In an open-label trial in patients with heart failure with preserved ejection fraction with left ventricular ejection fraction of 60% or greater, mavacamten, a cardiac myosin inhibitor, was associated with improvements in biomarkers of cardiac wall stress and injury, with no sustained reductions in left ventricular ejection fraction observed.

Corresponding Authors: To contact the corresponding authors, email Sanjiv J. Shah, MD, (sanjiv.shah@northwestern.edu) and Scott D. Solomon, MD, (ssolomon@bwh.harvard.edu).

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamacardio.2024.3810)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

# # #

Media advisory: This study is being presented at the Heart Failure Society of America Annual Scientific Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2024.3810?guestAccessKey=90c1d87e-0a72-447a-b6a6-e9cdb9d39cbb&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=093024

END

ELSE PRESS RELEASES FROM THIS DATE:

Amy Vandiver, MD, PhD, of UCLA receives the 2024 Sagol Network GerOmic Award for Junior Faculty

2024-09-30

NEW YORK — The American Federation for Aging Research (AFAR) is pleased to announce the recipient of the 2024 Sagol Network GerOmic Award for Junior Faculty: Amy Vandiver, MD, PhD, Clinical Instructor Clinician-Investigator Track, University of California Los Angeles. Established in 2020, the Sagol Network GerOmic Award for Junior Faculty is a one- to two-year award given to junior faculty (MDs and PhDs) to conduct aging-related Omics (GerOmics) research. Omics is a rapidly evolving, multi-disciplinary, and emerging field that encompasses genomics, epigenomics, transcriptomics, ...

Post-mastectomy radiation therapy can be shortened by nearly half for patients planning breast reconstruction

2024-09-30

WASHINGTON, September 30, 2024 — An accelerated course of radiation therapy does not increase complications for patients who undergo breast reconstruction following a mastectomy, new research shows. Findings of the large, phase III RT CHARM trial (Alliance A221505) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting. While radiation therapy following mastectomy to remove breast cancer is known to improve survival rates for certain patients who are at higher risk of recurrence, RT CHARM is the first multi-institutional international study to show that a shorter course ...

IMRT and proton therapy offer equally high quality of life and tumor control for people with prostate cancer

2024-09-30

WASHINGTON, September 30, 2024 — People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation therapy — proton beam therapy or intensity modulated radiation therapy (IMRT) — achieved equally high rates of tumor control with no differences in patient-reported quality of life, according to a first-of-its-kind phase III clinical trial comparing the two technologies. Findings of the PARTIQoL trial will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting. “We tested two contemporary, advanced forms of external ...

Timing matters when adding immunotherapy to chemoradiation for patients with limited-stage small cell lung cancer

2024-09-30

WASHINGTON, September 30, 2024 — People with limited-stage small cell lung cancer may benefit from adding immunotherapy to chemoradiation, but not if both treatments are given at the same time, new research finds. The results suggest that the timing of when immunotherapy is given plays a key role in its ability to extend survival. Findings of the multi-institutional phase III trial, which also found that twice-daily radiation treatments offer greater survival benefits than once-daily treatment, will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting. The ...

Existing standard chemoradiation superior to deintensification approaches for HPV-related oropharyngeal cancer

2024-09-30

WASHINGTON, September 30, 2024 — Researchers looking to de-intensify radiation treatments for people with early-stage, HPV-associated oropharyngeal cancer to prevent long-term side effects halted a large, randomized phase II/III trial after patients in the control arm reached a record high, two-year progression-free survival rate of 98%. De-intensified treatments involving a lower radiation dose and immunotherapy in place of chemotherapy did not perform as well as the more rigorous chemoradiation approach. Findings of the NRG Oncology HN005 trial will be presented today at the American Society for Radiation Oncology (ASTRO) Annual ...

CAR-T safe and effective on an outpatient basis in community hospitals

2024-09-30

(WASHINGTON – September 30, 2024) In the largest prospective study to date examining the use of chimeric antigen receptor (CAR)-T therapy in a community setting on an outpatient basis, patients with relapsed or refractory large B-cell lymphoma (LBCL) responded well to treatment with few serious side effects, according to results published today in Blood Advances. LBCL is a cancer affecting B lymphocytes, a type of white blood cell. It can progress rapidly and is fatal if untreated, although most forms of LBCL respond well to standard ...

City of Hope to present leading-edge radiotherapy treatments for people with lung, genitourinary and blood cancers at the American Society for Radiation Oncology Annual Meeting

2024-09-30

LOS ANGELES — City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S. and ranked among the nation’s top 5 cancer centers by U.S. News & World Report, is part of today’s press conference program at the American Society for Radiation Oncology (ASTRO) Annual Meeting, where a renowned City of Hope radiation oncologist will present phase 3 clinical trial data showing that people with limited-stage small cell lung cancer may benefit from adding immunotherapy to chemoradiation, but not if both treatments are given at the same time. The results suggest that the timing of when immunotherapy is given plays a key role in its ...

A new and unique fusion reactor comes together with PPPL's contributions

2024-09-30

Like atoms coming together to release their power, fusion researchers worldwide are joining forces to solve the world’s energy crisis. Harnessing the power of fusing plasma as a reliable energy source for the power grid is no easy task, requiring global contributions. The Princeton Plasma Physics Laboratory (PPPL) — a U.S. national laboratory funded by the Department of Energy (DOE) — is leading several efforts on this front, including collaborating on the design and development of a new fusion device at the University of Seville in Spain. The SMall Aspect Ratio Tokamak (SMART) strongly ...

Reduced risk of serious cardiovascular disease after COVID vaccination

2024-09-30

People who have been fully vaccinated against COVID-19 have a significantly lower risk of developing more severe cardiovascular conditions linked to COVID-19 infection, according to a nationwide study at the University of Gothenburg. At the same time, some cardiovascular effects are seen after individual doses of the vaccine. The COVID-19 vaccine aims to reduce complications and overall mortality from the disease. At the same time, some cardiovascular effects have been seen after individual doses of the vaccine. A rare acute side effect is inflammation of the cardiac muscle or the pericardium in young men following mRNA vaccination. In terms of other cardiovascular ...

New laser-based headset can measure blood flow, assess risk of stroke

2024-09-30

When physicians want to know more about a patient’s risk of cardiovascular disease, they can order a cardiac stress test. But when it comes to risk of stroke, there is no equivalent scalable and cost-effective test of the brain’s function to help physicians counsel patients on their potential risk. A questionnaire that asks patients about contributing risk factors is currently the best tool for estimating such risk. Now a team of engineers and scientists from Caltech and the Keck School ...

LAST 30 PRESS RELEASES:

ECMWF and European Partners win prestigious HPCwire Award for "Best Use Of AI Methods for Augmenting HPC Applications” – for AI innovation in weather and climate